Results 21 to 30 of about 101,527 (239)
Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse [PDF]
, 2011 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
BB Dawood +43 more
core +4 more sources
Clinical experience with cyclooxygenase-2 inhibitors [PDF]
Rheumatology, 2002 Rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic conditions requiring long-term therapy for pain relief. Currently prescribed non-steroidal anti-inflammatory drugs (NSAIDs) provide symptomatic efficacy, but are frequently associated with gastrointestinal (GI) toxicities such as dyspepsia and ulcerations.
openaire +3 more sources
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Understanding the NSAID related risk of vascular events [PDF]
, 2006 Concern is growing about an increased risk of thrombotic events (including myocardial infarction and stroke) during the use of non-steroidal anti-inflammatory drugs (NSAIDs), in particular the so called selective cyclo-oxygenase-2 (COX 2) inhibitors ...
Brouwers, Jacobus R.B.J. +2 more
core +4 more sources
Molecular Oncology, EarlyView.Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam +2 more
wiley +1 more source
In Silico screening of nonsteroidal anti-inflammatory drugs and their combined action on Prostaglandin H Synthase-1 [PDF]
, 2010 The detailed kinetic model of Prostaglandin H Synthase-1 (PGHS-1) was applied to in silico screening of dose-dependencies for the different types of nonsteroidal anti-inflammatory drugs (NSAIDs), such as: reversible/irreversible, nonselective/selective ...
Demin, Oleg +5 more
core +4 more sources
Molecular Oncology, EarlyView.This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou +13 more
wiley +1 more source
A structure-based drug design approach for the identification of novel selective Cyclooxygenase-2 inhibitors using resveratrol analogues as lead molecules [PDF]
, 2015 Therapeutic areas for selective cyclooxygenase-2 inhibitors include inflammatory conditions and cancer. A study has demonstrated that hydroxylated analogues of resveratrol, which is found in red wine, inhibit cyclooxygenase-2 selectively.
Caruana, Clarissa, Shoemake, Claire
core
Non-steroidal anti-inflammatory drugs—changes in prescribing may be warranted [PDF]
, 2006 No abstract ...
Madhok, R. +3 more
core +1 more source
Molecular Oncology, EarlyView.Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy +12 more
wiley +1 more source